Clinical Trial

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Study acronym: SEACRAFT-1
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2023-06-07; most recent amendment 2026-02-24.
Status change: Recruiting → Active, Not Recruiting 2025-05-21
Status change: Not Yet Recruiting → Recruiting 2023-08-25
Trial Details
NCT Number NCT05907304
Lead Sponsor Erasca, Inc.
Conditions Advanced or Metastatic Solid Tumors
Enrollment 86 participants
Start Date 2023-08-17
Primary Completion 2025-07-01 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-27